USFDA27 Jun 2026, 11:00 am
Aurobindo Pharma Subsidiary Completes US FDA Inspection
AI Summary
Aurobindo Pharma Ltd announced the completion of a US FDA inspection at its wholly owned subsidiary, Auroactive Pharma Private Limited. The facility manufactures Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates. The inspection, conducted from June 22 to June 26, 2026, concluded with 2 observations. Aurobindo Pharma stated that they will respond to these observations within the stipulated time and are committed to maintaining high manufacturing standards. The company confirmed there is no impact on its financials or operations due to this inspection. Further information will be provided if necessary.
Key Highlights
- US FDA inspection completed at Aurobindo Pharma subsidiary.
- Facility manufactures API & Pharmaceutical Formulation Intermediates.
- Inspection concluded with 2 observations.
- No financial or operational impact reported.
- Company committed to high quality manufacturing standards.
Price Impact
More from AUROPHARMA